Suppr超能文献

改良英国医学研究委员会呼吸困难量表表明,特发性肺纤维化患者的生活质量受损且疼痛加剧。

mMRC dyspnoea scale indicates impaired quality of life and increased pain in patients with idiopathic pulmonary fibrosis.

作者信息

Rajala Kaisa, Lehto Juho T, Sutinen Eva, Kautiainen Hannu, Myllärniemi Marjukka, Saarto Tiina

机构信息

Helsinki University Hospital, Comprehensive Cancer Center, Dept of Palliative Care, Helsinki, Finland.

Faculty of Medicine, University of Helsinki, Helsinki, Finland.

出版信息

ERJ Open Res. 2017 Dec 14;3(4). doi: 10.1183/23120541.00084-2017. eCollection 2017 Oct.

Abstract

This study was undertaken to investigate idiopathic pulmonary fibrosis (IPF) patients' health-related quality of life (HRQoL) and symptoms in a real-life cross-sectional study. Our secondary aim was to create a simple identification method for patients with increased need for palliative care by studying the relationship between modified Medical Research Council (mMRC) dyspnoea scale, HRQoL and symptoms. We sent a self-rating HRQoL questionnaire (RAND-36) and modified Edmonton Symptom Assessment Scale (ESAS) to 300 IPF patients; 84% of the patients responded to these questionnaires. The most prevalent (>80%) symptoms were tiredness, breathlessness, cough and pain in movement. An increasing mMRC score showed a linear relationship (p<0.001) to impaired HRQoL in all dimensions of RAND-36 and the severity of all symptoms in ESAS. Dimensions of RAND-36 fell below general population reference values in patients with mMRC score ≥2. The intensity of pain in movement (p<0.001) and at rest (p=0.041), and the prevalence of chest pain (p<0.001) had a positive linear relationship to increased mMRC score. An increasing mMRC score reflects impaired HRQoL and a high symptom burden. In clinical practice, the mMRC scale could be used for screening and identification of IPF patients with increased need for palliative care.

摘要

本研究旨在通过一项现实生活中的横断面研究,调查特发性肺纤维化(IPF)患者的健康相关生活质量(HRQoL)和症状。我们的次要目标是通过研究改良医学研究委员会(mMRC)呼吸困难量表、HRQoL和症状之间的关系,创建一种针对姑息治疗需求增加的患者的简单识别方法。我们向300名IPF患者发送了一份HRQoL自评问卷(RAND-36)和改良的埃德蒙顿症状评估量表(ESAS);84%的患者对这些问卷做出了回应。最常见(>80%)的症状是疲劳、呼吸困难、咳嗽和运动时疼痛。mMRC评分增加与RAND-36所有维度的HRQoL受损以及ESAS中所有症状的严重程度呈线性关系(p<0.001)。mMRC评分≥2的患者,RAND-36的维度低于一般人群参考值。运动时(p<0.001)和休息时(p=0.041)的疼痛强度以及胸痛的患病率(p<0.001)与mMRC评分增加呈正线性关系。mMRC评分增加反映了HRQoL受损和高症状负担。在临床实践中,mMRC量表可用于筛查和识别姑息治疗需求增加的IPF患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8345/5731772/a3cbf118378d/00084-2017.01.jpg

相似文献

1
mMRC dyspnoea scale indicates impaired quality of life and increased pain in patients with idiopathic pulmonary fibrosis.
ERJ Open Res. 2017 Dec 14;3(4). doi: 10.1183/23120541.00084-2017. eCollection 2017 Oct.
3
6
Factor analysis identifies three separate symptom clusters in idiopathic pulmonary fibrosis.
ERJ Open Res. 2020 Oct 5;6(4). doi: 10.1183/23120541.00347-2020. eCollection 2020 Oct.
7
Health-Related Quality of Life in Patients with Idiopathic Pulmonary Fibrosis.
Lung. 2016 Apr;194(2):227-34. doi: 10.1007/s00408-016-9850-y. Epub 2016 Feb 9.
8
Health-related quality of life in idiopathic pulmonary fibrosis: Data from the Australian IPF Registry.
Respirology. 2017 Jul;22(5):950-956. doi: 10.1111/resp.12989. Epub 2017 Feb 6.

引用本文的文献

1
Association of Mood or Affect With Respiratory-Related Quality of Life, Lung Function, and All-Cause Mortality in Fibrotic Interstitial Lung Disease.
Mayo Clin Proc Innov Qual Outcomes. 2025 Aug 29;9(5):100660. doi: 10.1016/j.mayocpiqo.2025.100660. eCollection 2025 Oct.
4
Characteristics and Prevalence of Sequelae after COVID-19: A Longitudinal Cohort Study.
Infect Chemother. 2025 Mar;57(1):72-80. doi: 10.3947/ic.2024.0090.
10
Patient-centered care in pulmonary fibrosis: access, anticipate, and act.
Respir Res. 2024 Nov 1;25(1):395. doi: 10.1186/s12931-024-02997-7.

本文引用的文献

2
Impact of Comorbidities on Mortality in Patients with Idiopathic Pulmonary Fibrosis.
PLoS One. 2016 Mar 29;11(3):e0151425. doi: 10.1371/journal.pone.0151425. eCollection 2016.
3
End-of-life care in oxygen-dependent ILD compared with lung cancer: a national population-based study.
Thorax. 2016 Jun;71(6):510-6. doi: 10.1136/thoraxjnl-2015-207439. Epub 2016 Feb 10.
4
Health-Related Quality of Life in Patients with Idiopathic Pulmonary Fibrosis.
Lung. 2016 Apr;194(2):227-34. doi: 10.1007/s00408-016-9850-y. Epub 2016 Feb 9.
7
Modified Edmonton Symptom Assessment System including constipation and sleep: validation in outpatients with cancer.
J Pain Symptom Manage. 2015 May;49(5):945-52. doi: 10.1016/j.jpainsymman.2014.10.013. Epub 2014 Dec 15.
8
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
N Engl J Med. 2014 May 29;370(22):2083-92. doi: 10.1056/NEJMoa1402582. Epub 2014 May 18.
9
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
N Engl J Med. 2014 May 29;370(22):2071-82. doi: 10.1056/NEJMoa1402584. Epub 2014 May 18.
10
How does comorbidity influence survival in idiopathic pulmonary fibrosis?
Respir Med. 2014 Apr;108(4):647-53. doi: 10.1016/j.rmed.2014.01.008. Epub 2014 Feb 2.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验